M. Krahn

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Md Krahn, M Krahn, Murray Krahn, M. Krahn, Murray D Krahn, Murray D. Krahn, M. D. Krahn, M D Krahn
Publication record
559 papers · 17,964 citations · H-index 66

PAPERS

Cost-effectiveness of Fibrinogen Concentrate vs Cryoprecipitate for Treating Acquired Hypofibrinogenemia in Bleeding Adult Cardiac Surgical Patients
202316 citationsauthor #7
Fibrinogen Concentrate vs Cryoprecipitate for Treating Acquired Hypofibrinogenemia in Bleeding Adult Cardiac Surgical Patients: A Within-trial Economic Evaluation of the FIBRES Randomized Controlled Trial
20230 citationsauthor #8
A province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in Canada
20233 citationsauthor #5
Cost-effectiveness analysis of genetic tools to predict treatment response in patients with cystic fibrosis.
20232 citationsauthor #8
Impact of direct‐acting antiviral treatment on health utility in patients with chronic hepatitis C in hospital and community settings
20232 citationsauthor #14
Characterizing the cascade of care for hepatitis C virus infection among Status First Nations peoples in Ontario: a retrospective cohort study
202312 citationsauthor #3
Developing the Breast Utility Instrument to Measure Health-Related Quality-of-Life Preferences in Patients with Breast Cancer: Selecting the Item for Each Dimension
20222 citationsauthor #4
Developing the Breast Utility Instrument, a preference-based instrument to measure health-related quality of life in women with breast cancer: Confirmatory factor analysis of the EORTC QLQ-C30 and BR45 to establish dimensions
20229 citationsauthor #8
PO130 / #769 CONVENTIONAL MEDICAL MANAGEMENT VS CERVICAL SPINAL CORD STIMULATION FOR MANAGEMENT OF CHRONIC CLUSTER HEADACHE: A MARKOV DECISION ANALYSIS
20220 citationsauthor #3
Reliability and validity of using EQ-5D-5L among healthy and adolescents with major mental health disorders in Ethiopia
202218 citationsauthor #5
“Bring the Hoses to Where the Fire Is!”: Differential Impacts of Marginalization and Socioeconomic Status on COVID-19 Case Counts and Healthcare Costs
20226 citationsauthor #15
Disparities in health utilities among hepatitis C patients receiving care in different settings.
20225 citationsauthor #10
Abstract P4-10-22: Patient reported symptoms and functional status in breast cancer
20220 citationsauthor #6
No Time to Waste: An Appraisal of Value at the End of Life.
20227 citationsauthor #2
Initial health care costs for COVID-19 in British Columbia and Ontario, Canada: an interprovincial population-based cohort study
20227 citationsauthor #21
Lessons from First Nations partnerships in hepatitis C research and the co-creation of knowledge.
20223 citationsauthor #9
Abstract P4-12-11: Eq-5d-5l utility scores for patients with breast cancer
20220 citationsauthor #6
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations
202221 citationsauthor #62
Excess cost of care associated with sepsis in cancer patients: Results from a population-based case-control matched cohort
202115 citationsauthor #4
Economic evaluations and costing studies of lung transplantation: A scoping review.
202113 citationsauthor #3
Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT)
20213 citationsauthor #4
Time Costs and Out-of-Pocket Costs in Patients With Chronic Hepatitis C in a Publicly Funded Health System.
20215 citationsauthor #11
Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study
202110 citationsauthor #10
Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists
202116 citationsauthor #9
Hepatitis C virus infection in First Nations populations in Ontario from 2006 to 2014: a population-based retrospective cohort analysis
20215 citationsauthor #9
Health care costs associated with hepatitis C virus infection in First Nations populations in Ontario: a retrospective matched cohort study
20216 citationsauthor #9
Sex differences in direct healthcare costs following stroke: a population-based cohort study
202114 citationsauthor #2
Impact of direct‐acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta‐analysis
202130 citationsauthor #5
Association of Neighborhood-Level Material Deprivation With Health Care Costs and Outcome After Stroke
20217 citationsauthor #3
PCN123 5-Year Health Care Costs of Sepsis in Cancer Patients: Results from a Population-Based Case-Control Matched Cohort
20201 citationsauthor #4
Patterns of Care and Costs for Older Patients With Colorectal Cancer at the End of Life: Descriptive Study of the United States and Canada.
202011 citationsauthor #13
Exploring the Benefits of Transformations in Health Utility Mapping
20206 citationsauthor #4
Modes of coordination for health technology adoption: Health Technology Assessment agencies and Group Procurement Organizations in a polycentric regulatory regime.
20205 citationsauthor #5
Implementation, spread and impact of the Patient Oriented Discharge Summary (PODS) across Ontario hospitals: a mixed methods evaluation
202022 citationsauthor #4
Valuing Health State: An EQ-5D-5L Value Set for Ethiopians.
202074 citationsauthor #5
Value of mesenchymal stem cell therapy for patients with septic shock: an early health economic evaluation
202010 citationsauthor #3
PNS18 IMPROVING THE APPLICATION OF PUBLISHED HEALTH UTILITIES IN COST-UTILITY ANALYSES: DEVELOPMENT OF THE HEALTH UTILITY APPLICATION TOOL (HAT)
20200 citationsauthor #4
Understanding resource utilization and mortality in COPD to support policy making: A microsimulation study
20201 citationsauthor #5
Comparing Childhood Cancer Care Costs in Two Canadian Provinces
20207 citationsauthor #10
Pharmacological Acromegaly Treatment: Cost-Utility and Value of Information Analysis
20204 citationsauthor #3
A randomized controlled trial of an exercise maintenance intervention in men and women post-cardiac rehabilitation (ECO-PCR).
202013 citationsauthor #10
High-Cost Patients and Preventable Spending: A Population-Based Study.
202013 citationsauthor #5
Treatment of Chronic Hepatitis C in Young Children Reduces Adverse Outcomes and Is Cost-Effective Compared to Deferring Treatment to Adulthood.
202020 citationsauthor #4
The emergency department as a setting‐specific opportunity for population‐based hepatitis C screening: An economic evaluation
202023 citationsauthor #7
Incremental vs. average cost-effectiveness ratio: which one is preferable in health technology assessment?
20200 citationsauthor #3
Strategies to achieve population control of HCV infection: results of a multidisciplinary focus group.
20201 citationsauthor #4
Sepsis-Associated Mortality, Resource Use, and Healthcare Costs: A Propensity-Matched Cohort Study.
202075 citationsauthor #6
PRO8 MEDICATIONS FOR ACROMEGALY: COST-UTILITY AND VALUE OF INFORMATION ANALYSIS
20200 citationsauthor #3
Health-Related Quality of Life Changes Associated With Hearing Loss.
202073 citationsauthor #6
The health impact of delaying direct‐acting antiviral treatment for chronic hepatitis C: A decision‐analytic approach
20208 citationsauthor #5
On the integration of early health technology assessment in the innovation process: reflections from five stakeholders
202019 citationsauthor #5
Estimating chronic hepatitis C prevalence in British Columbia and Ontario, Canada, using population‐based cohort studies
202013 citationsauthor #6
Challenges in the adoption of regenerative medicine therapies, meeting summary
20201 citationsauthor #5
Mapping the EORTC QLQ‐C30 and QLQ‐H&N35, onto EQ‐5D‐5L and HUI‐3 indices in patients with head and neck cancer
202018 citationsauthor #5
Long‐term morbidity and mortality in a Canadian post‐transfusion hepatitis C cohort: Over 15 years of follow‐up
20202 citationsauthor #6
Direct and indirect utilities of patients with mild to moderate versus severe carpal tunnel syndrome
20203 citationsauthor #3
A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C.
202033 citationsauthor #9
Effects of six months of aerobic and resistance training on metabolic markers and bone mineral density in older men on androgen deprivation therapy for prostate cancer.
202014 citationsauthor #7
Review of Pharmacoeconomic Studies in Russian Cancer Research: An Outside View.
20190 citationsauthor #3
Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials
201932 citationsauthor #14
MP14-04 RENAL BIOPSY - WHEN WILL IT CHANGE MANAGEMENT?
20190 citationsauthor #10
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
201992 citationsauthor #3
Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB)
201920 citationsauthor #5
Mapping the University of Washington Quality of life questionnaire onto EQ‐5D and HUI‐3 indices in patients with head and neck cancer
201912 citationsauthor #5
CLINICAL AND COST-EFFECTIVENESS OF COMPREHENSIVE GERIATRIC ASSESSMENT AND MANAGEMENT FOR CANADIAN ELDERS WITH CANCER: THE 5C STUDY – INITIAL RECRUITMENT AND IMPLEMENTATION RESULTS
20190 citationsauthor #17
Clinical and Cost-effectiveness of a Comprehensive geriatric assessment and management for Canadian elders with Cancer—the 5C study: a study protocol for a randomised controlled phase III trial
201927 citationsauthor #15
SIESTA - Home sleep study with BresoDx for obstructive sleep apnea: a randomized controlled trial.
201911 citationsauthor #14
PCN41 THE HEALTH UTILITY BOOK (HUB): A REGISTRY OF HEALTH STATE UTILITY VALUES IN ONCOLOGY
20190 citationsauthor #5
Home Dialysis Is Associated with Lower Costs and Better Survival than Other Modalities: A Population-Based Study in Ontario, Canada
201945 citationsauthor #1
The Effect of Cardiac Rehabilitation on Health-Related Quality of Life in Patients With Coronary Artery Disease: A Meta-analysis.
2019102 citationsauthor #8
Health Utility Book (HUB)–Cancer: Protocol for a Systematic Literature Review of Health State Utility Values in Cancer
20194 citationsauthor #5
Comparative effectiveness of the different components of care provided in heart failure clinics—protocol for a systematic review and network meta-analysis
20194 citationsauthor #11
PCN42 THE HEALTH UTILITY BOOK (HUB): TOWARD A CENTRALIZED, SYSTEMATIC APPROACH TO THE IDENTIFICATION, APPRAISAL, AND USE OF HEALTH STATE UTILITY VALUES FOR REIMBURSEMENT DECISION MAKING
20190 citationsauthor #5
Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update
201938 citationsauthor #2
How Procurement Judges The Value of Medical Technologies: A Review of Healthcare Tenders
201925 citationsauthor #8
OP78 Picturing ELSI+: Mapping Ethical, Legal, Social And Value Issues
20191 citationsauthor #1
A model-based framework for chronic hepatitis C prevalence estimation
20198 citationsauthor #3
Chlorhexidine-Related Mortality Rate in Critically Ill Subjects in Intensive Care Units: A Systematic Review and Meta-Analysis
201919 citationsauthor #5
Picturing ELSI+: a visual representation of ethical, legal, and social issues, and patient experiences in Health Technology Assessment in Canada
20191 citationsauthor #1
New Insights into the Epidemiology of Prostate Cancer in Ontario
20191 citationsauthor #6
Using a Health Economic Framework to Prioritize Quality Indicators: An Example With Smoking Cessation in Chronic Obstructive Pulmonary Disease
20190 citationsauthor #4
MP41-20 DISEASE-SPECIFIC COSTS OF NONMETASTATIC AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN QUEBEC
20190 citationsauthor #10
A phase II randomized controlled trial of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy
201943 citationsauthor #6
PCN252 QUALITY EVALUATION OF PHARMACOECONOMIC STUDIES IN RUSSIAN CANCER RESEARCH: AN OUTSIDE VIEW
20190 citationsauthor #3
Prioritizing Quality Indicators By Population Net Health Benefit: An Example with Oxygen Therapy in Chronic Obstructive Pulmonary Disease
20180 citationsauthor #4
Lifetime cost of chronic ulcers requiring hospitalization in Ontario, Canada: A population-based study
20185 citationsauthor #5
Future Directions for Cost-effectiveness Analyses in Health and Medicine
201862 citationsauthor #10
Cost comparison on of TURP and Greenlight for BPH Cost analysis of Greenlight photoselective vaporization of the prostate compared to transurethral resection of the prostate for benign prostatic hyperplasia
20181 citationsauthor #3
Methods for identifying health state transitions from administrative data: the case of metastasis in prostate cancer
20180 citationsauthor #7
Advances in Prostate Cancer
20180 citationsauthor #5
Costs and Survival for Dialysis Patients: Real World Evidence Supporting Home Dialysis
20181 citationsauthor #1
Cost Utility Analysis of Genetic Testing for Breast Cancer Gene Mutations in a Two-Step Process Compared to Genetic Testing in a One-Step 20- Cancer Gene Panel to Detect New Breast Cancer Cases Amongst Women with a High Lifetime Risk
20180 citationsauthor #10
DEVELOPMENT OF THE ONTARIO DECISION FRAMEWORK: A VALUES BASED FRAMEWORK FOR HEALTH TECHNOLOGY ASSESSMENT
201817 citationsauthor #1
Diagnostic accuracy of level IV portable sleep monitors versus polysomnography for obstructive sleep apnea: a systematic review and meta-analysis
201854 citationsauthor #9
The economic burden of cancer care in Canada: a population-based cost study.
201895 citationsauthor #4
Gender Differences in Utilization of Specialized Heart Failure Clinics
201818 citationsauthor #4
Turning High‐Risk Individuals: An Economic Evaluation of Repositioning Frequency in Long‐Term Care
20181 citationsauthor #6
Comparative Effectiveness of the Core Components of Cardiac Rehabilitation on Mortality and Morbidity: A Systematic Review and Network Meta-Analysis
2018156 citationsauthor #10
Pharmacotherapy vs surgery as initial therapy for patients with moderate‐to‐severe benign prostate hyperplasia: a cost‐effectiveness analysis
201822 citationsauthor #3
Effects of a 6-month moderate-intensity exercise program on metabolic parameters and bone mineral density in men on androgen deprivation therapy for prostate cancer.
20182 citationsauthor #7

TIMELINE

1991 0 citations

1992 10 citations

1993 73 citations

1994 18 citations

1995 2 citations

1996 6 citations

1997 962 citations

1998 146 citations

1999 83 citations

2000 227 citations

2001 31 citations

2002 197 citations

2003 976 citations

2004 725 citations

2005 344 citations

2006 534 citations

2007 363 citations

2008 1,403 citations

2009 793 citations

2010 1,143 citations

2011 775 citations

2012 1,349 citations

2013 663 citations

2014 841 citations

2015 441 citations

2016 3,502 citations

2017 518 citations

2018 579 citations

2019 485 citations

2020 470 citations

2021 124 citations

2022 78 citations

2023 35 citations

M. Krahn

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT